Gastroenterology Research and Practice / 2017 / Article / Tab 6 / Research Article
Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis Table 6 Univariate and multivariate analysis of survival outcomes in overall GCLM and of the subgroup of serum AFP ≥ 20 ng/ml.
GCLM with serum AFP ≥ 20 ng/ml ( ) Overall GCLM ( ) Univariate analysis (KM) Multivariate analysis (Cox) Univariate analysis (KM) Multivariate analysis (Cox) Variable mOS (m) valueHR 95% CI valuemOS (m) valueHR 95%CI valueGender Male 9.9 0.608 14.1 0.609 Female 15.1 14.8 Age ≤65 9.2 0.773 14.8 0.379 >65 11.3 14.9 ECOG 0-1 9.2 0.095 16.5 0.227 2-3 11.3 14.5 Disease status LM after radical resection 10.4 0.411 19.3 0.046 0.700 0.359–1.364 0.295 LM at first diagnosis 10.9 14.5 Primary lesion site GEJ 14.9 0.103 15.2 0.600 Non-GEJ 9.4 14.5 Histologic classification Intestinal 12.7 0.757 16.1 0.021 0.558 0.370–0.840 0.005 Nonintestinal 12.0 11.2 HER2 status Positive 12.7 0.888 17.3 0.293 Negative 15.1 15.2 Extrahepatic M Present 10.4 0.116 14.6 0.952 Absent 12.2 15.5 Peritoneal M Present 4.6 <0.001 4.411 1.817–10.712 0.001 10.8 0.001 1.953 1.105–3.451 0.021 Absent 11.3 15.4 LM numbers 1–3 17.6 0.115 19.5 0.002 0.416 0.236–0.733 0.002 >3 9.9 12.7 First-line chemo regimen Doublet regimen 9.9 0.157 14.9 0.816 Triplet regimen 37.6 17.3 Response to first-line chemo PR 15.4 0.017 0.328 0.173–0.624 0.001 19.2 <0.001 0.506 0.334–0.768 0.001 SD + PD 9.4 11.4 Local treatment for LM Yes 19.2 0.003 0.356 0.179–0.710 0.003 20.8 <0.001 0.623 0.394–0.986 0.043 No 8.4 12.4 Serum AFP level (ng/ml) ≥20 ng/ml 10.9 0.004 1.553 1.006–2.397 0.047 <20 ng/ml 15.7